LG Life Sciences Expands Diabetes Drug Market To 104 Countries
This article was originally published in PharmAsia News
LG Life Sciences has reached an outlicensing deal with Mexico's Stendhal to market the Zemiglo (gemigliptin) and ZemiMet diabetes drugs in 23 Central and South America countries.
You may also be interested in...
EXACT-Tx will use funds from a NOK155m private placing to harness ultrasound in precision therapeutic targeting across a variety of indications and product classes.
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. The first of a two-part series on mental health focuses on transcranial magnetic stimulation systems. See what Neuronetics’ CEO Stephen Furlong said about it here.